Key Highlights
- Collaboration Revenue of USD 10.2 million topped the consensus estimate of USD 7.58 million and the prior quarter.
- Loss per share of USD 1.05 was narrower than the USD 1.18 consensus estimate, while GAAP loss was USD 1.22.
- Net loss widened to USD 125.7 million from USD 112.5 million last quarter, with R&D at USD 121.6 million.
- Cash and marketable securities stood at USD 1.15 billion, and cash runway guidance into 2030 was left unchanged.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) reported third quarter 2026 collaboration revenue of USD 10.2 million, above a consensus estimate of USD 7.58 million and up from USD 8.9 million in the second quarter. Loss per share of USD 1.05 compared with a consensus estimate of a USD 1.18 loss. The GAAP net loss was USD 125.7 million, or USD 1.22 per diluted share, versus a net loss of USD 112.5 million, or USD 1.22 per share, in the second quarter. Revenue was recognized under the Servier exclusive license agreement for darovasertib, with USD 139.8 million of related performance obligations remaining.
Spending Rises as Late Stage Programs Advance
Research and development expense rose to USD 121.6 million from USD 108.7 million in the second quarter on higher clinical trial, development and personnel costs. General and administrative expense increased to USD 26.3 million from USD 22.5 million, reflecting higher personnel costs and darovasertib commercial preparation. Loss from operations was USD 137.6 million, partly offset by USD 11.9 million of interest and other income. Stock-based compensation totaled USD 17.7 million against USD 16.7 million. Over nine months the net loss reached USD 336.7 million versus USD 30.4 million a year earlier, when collaboration revenue was USD 207.8 million rather than USD 25.7 million. Chief Executive Officer Yujiro Hata pointed to the completed first new drug application filing for darovasertib in metastatic uveal melanoma and the clinical updates at the ESMO congress.
Pipeline Milestones and Cost Reallocation
The company submitted the darovasertib plus crizotinib application to the FDA under the Real-Time Oncology Review program. It decided to close the Phase 3 OptimUM-010 trial because of site activation and enrollment challenges, a move it estimates saves USD 100 to 125 million redirected to other programs, including potential registrational trials for IDE849 and IDE892. A global Phase 3 trial, OptimUM-011, is enrolling about 450 patients with primary uveal melanoma in the adjuvant setting. For IDE849, a DLL3 TOP1 antibody drug conjugate, a partner-sponsored Phase 1 study showed median overall survival of 17.4 months in second line small cell lung cancer, and the company plans two Phase 3 trials by year end. Initial data from its own global Phase 1/2 trial are scheduled for the end of 2026 or early 2027.
Cash Position and Dated Events Against Prior Marks
Cash, cash equivalents and marketable securities were USD 1.15 billion on September 30, 2026, against USD 1.24 billion on June 30 and USD 1.05 billion at the end of 2025. Total liabilities were USD 124.0 million against USD 86.4 million at year end. An R&D Day on November 16 is scheduled to cover preclinical data on MTAP/CDKN2A deficiency in KRAS-mutant cancers. A Phase 1 trial of IDE892 with a Roche pan-RAS inhibitor is targeted for initiation by the end of 2026, and initial IDE034 clinical data are scheduled for 2027. Remaining Servier performance obligations of USD 139.8 million compare with USD 10.2 million of revenue recognized in the quarter.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...